#BEGIN_DRUGCARD DB00426

# AHFS_Codes:
08:18.32

# ATC_Codes:
J05AB09
S01AD07

# Absorption:
77 %

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Famvir

# CAS_Registry_Number:
104227-87-4

# ChEBI_ID:
4974

# Chemical_Formula:
C14H19N5O4

# Chemical_IUPAC_Name:
2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2229110

# Description:
Famciclovir is a guanine analogue antiviral drug used for the treatment of various herpes virus infections, most commonly for herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis).

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Antiviral Agents
Nucleosides and Nucleotides
Prodrugs

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Famciclovir

# HET_ID:
Not Available

# Half_Life:
10 hours

# InChI_Identifier:
InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)

# InChI_Key:
InChIKey=GGXKWVWZWMLJEH-UHFFFAOYSA-N

# Indication:
For the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00317

# LIMS_Drug_ID:
426

# Mechanism_Of_Action:
Famciclovir undergoes rapid biotransformation to the active antiviral compound penciclovir, which has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV). In cells infected with HSV-1, HSV-2 or VZV, viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted to penciclovir triphosphate by cellular kinases. In vitro studies demonstrate that penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited.

# Melting_Point:
102-104 Â°C

# Molecular_Weight_Avg:
321.3318

# Molecular_Weight_Mono:
321.143704121

# Organisms_Affected:
Human Herpes Virus

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449585

# Pharmacology:
Famciclovir is a prodrug that undergoes rapid biotransformation to the active antiviral compound penciclovir. Penciclovir is an anti-viral drug which has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV). Therefore, herpes viral DNA synthesis and replication are selectively inhibited.

# Predicted_LogP_Hydrophobicity:
0.13

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
1.32e+00 g/l

# Primary_Accession_No:
DB00426

# Protein_Binding:
20-25%

# PubChem_Compound_ID:
3324

# PubChem_Substance_ID:
46507561

# RxList_Link:
http://www.rxlist.com/cgi/generic3/famciclovir.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00600

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)OCC(CCN1C=NC2=CN=C(N)N=C12)COC(C)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
FCV
Famciclovirum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include constipation, diarrhea, dizziness, fatigue, fever, headache, nausea, and vomiting.

# Update_Date:
2013-02-08 16:19:20 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Famciclovir

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
AOX1

# Phase_1_Metabolizing_Enzyme_2_ID:
6020

# Phase_1_Metabolizing_Enzyme_2_Name:
Aldehyde oxidase

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Aldehyde oxidase
MDRASELLFYVNGRKVIEKNVDPETMLLPYLRKKLRLTGTKYGCGGGGCGACTVMISRYN
PITKRIRHHPANACLIPICSLYGAAVTTVEGIGSTHTRIHPVQERIAKCHGTQCGFCTPG
MVMSIYTLLRNHPEPTLDQLTDALGGNLCRCTGYRPIIDACKTFCKTSGCCQSKENGVCC
LDQGINGLPEFEEGSKTSPKLFAEEEFLPLDPTQELIFPPELMIMAEKQSQRTRVFGSER
MMWFSPVTLKELLEFKFKYPQAPVIMGNTSVGPEVKFKGVFHPVIISPDRIEELSVVNHA
YNGLTLGAGLSLAQVKDILADVVQKLPEEKTQMYHALLKHLGTLAGSQIRNMASLGGHII
SRHPDSDLNPILAVGNCTLNLLSKEGKRQIPLNEQFLSKCPNADLKPQEILVSVNIPYSR
KWEFVSAFRQAQRQENALAIVNSGMRVFFGEGDGIIRELCISYGGVGPATICAKNSCQKL
IGRHWNEQMLDIACRLILNEVSLLGSAPGGKVEFKRTLIISFLFKFYLEVSQILKKMDPV
HYPSLADKYESALEDLHSKHHCSTLKYQNIGPKQHPEDPIGHPIMHLSGVKHATGEAIYC
DDMPLVDQELFLTFVTSSRAHAKIVSIDLSEALSMPGVVDIMTAEHLSDVNSFCFFTEAE
KFLATDKVFCVGQLVCAVLADSEVQAKRAAKRVKIVYQDLEPLILTIEESIQHNSSFKPE
RKLEYGNVDEAFKVVDQILEGEIHMGGQEHFYMETQSMLVVPKGEDQEMDVYVSTQFPKY
IQDIVASTLKLPANKVMCHVRRVGGAFGGKVLKTGIIAAVTAFAANKHGRAVRCVLERGE
DMLITGGRHPYLGKYKAGFMNDGRILALDMEHYSNAGASLDESLFVIEMGLLKMDNAYKF
PNLRCRGWACRTNLPSNTAFRGFGFPQAALITESCITEVAAKCGLSPEKVRIINMYKEID
QTPYKQEINAKNLIQCWRECMAMSSYSLRKVAVEKFNAENYWKKKGLAMVPLKFPVGLGS
RAAGQAAALVHIYLDGSVLVTHGGIEMGQGVHTKMIQVVSRELRMPMSNVHLRGTSTETV
PNANISGGSVVADLNGLAVKDACQTLLKRLEPIISKNPKGTWKDWAQTAFDESINLSAVG
YFRGYESDMNWEKGEGQPFEYFVYGAACSEVEIDCLTGDHKNIRTDIVMDVGCSINPAID
IGQIEGAFIQGMGLYTIEELNYSPQGILHTRGPDQYKIPAICDMPTELHIALLPPSQNSN
TLYSSKGLGESGVFLGCSVFFAIHDAVSAARQERGLHGPLTLNSPLTPEKIRMACEDKFT
KMIPRDEPGSYVPWNVPI

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
Q06278

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15452407	Schmid-Wendtner MH, Korting HC: Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X14112

# Drug_Target_1_GenBank_ID_Protein:
59530

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
UL30

# Drug_Target_1_Gene_Sequence:
>3708 bp
ATGTTTTCCGGTGGCGGCGGCCCGCTGTCCCCCGGAGGAAAGTCGGCGGCCAGGGCGGCG
TCCGGGTTTTTTGCGCCCGCCGGCCCTCGCGGAGCCAGCCGGGGACCCCCGCCTTGTTTG
AGGCAAAACTTTTACAACCCCTACCTCGCCCCAGTCGGGACGCAACAGAAGCCGACCGGG
CCAACCCAGCGCCATACGTACTATAGCGAATGCGATGAATTTCGATTCATCGCCCCGCGG
GTGCTGGACGAGGATGCCCCCCCGGAGAAGCGCGCCGGGGTGCACGACGGTCACCTCAAG
CGCGCCCCCAAGGTGTACTGCGGGGGGGACGAGCGCGACGTCCTCCGCGTCGGGTCGGGC
GGCTTCTGGCCGCGGCGCTCGCGCCTGTGGGGCGGCGTGGACCACGCCCCGGCGGGGTTC
AACCCCACCGTCACCGTCTTTCACGTGTACGACATCCTGGAGAACGTGGAGCACGCGTAC
GGCATGCGCGCGGCCCAGTTCCACGCGCGGTTTATGGACGCCATCACACCGACGGGGACC
GTCATCACGCTCCTGGGCCTGACTCCGGAAGGCCACCGGGTGGCCGTTCACGTTTACGGC
ACGCGGCAGTACTTTTACATGAACAAGGAGGAGGTCGACAGGCACCTACAATGCCGCGCC
CCACGAGATCTCTGCGAGCGCATGGCCGCGGCCCTGCGCGAGTCCCCGGGCGCGTCGTTC
CGCGGCATCTCCGCGGACCACTTCGAGGCGGAGGTGGTGGAGCGCACCGACGTGTACTAC
TACGAGACGCGCCCCGCTCTGTTTTACCGCGTCTACGTCCGAAGCGGGCGTGTGCTGTCG
TACCTGTGCGACAACTTCTGCCCGGCCATCAAGAAGTACGAGGGTGGGGTCGACGCCACC
ACCCGGTTCATCCTGGACAACCCCGGGTTCGTCACCTTCGGCTGGTACCGTCTCAAACCG
GGCCGGAACAACACGCTAGCCCAGCCGGCGGCCCCGATGGCCTTCGGGACATCCAGCGAC
GTCGAGTTTAACTGTACGGCGGACAACCTGGCCATCGAGGGGGGCATGAGCGACCTACCG
GCATACAAGCTCATGTGCTTCGATATCGAATGCAAGGCGGGGGGGGAGGACGAGCTGGCC
TTTCCGGTGGCCGGGCACCCGGAGGACCTGGTCATCCAGATATCCTGTCTGCTCTACGAC
CTGTCCACCACCGCCCTGGAGCACGTCCTCCTGTTTTCGCTCGGTTCCTGCGACCTCCCC
GAATCCCACCTGAACGAGCTGGCGGCCAGGGGCCTGCCCACGCCCGTGGTTCTGGAATTC
GACAGCGAATTCGAGATGCTGTTGGCCTTCATGACCCTTGTGAAACAGTACGGCCCCGAG
TTCGTGACCGGGTACAACATCATCAACTTCGACTGGCCCTTCTTGCTGGCCAAGCTGACG
GACATTTACAAGGTCCCCCTGGACGGGTACGGCCGCATGAACGGCCGGGGCGTGTTTCGC
GTGTGGGACATAGGCCAGAGCCACTTCCAGAAGCGCAGCAAGATAAAGGTGAACGGCATG
GTGAACATCGACATGTACGGGATTATAACCGACAAGATCAAGCTCTCGAGCTACAAGCTC
AACGCCGTGGCCGAAGCCGTCCTGAAGGACAAGAAGAAGGACCTGAGCTATCGCGACATC
CCCGCCTACTACGCCGCCGGGCCCGCGCAACGCGGGGTGATCGGCGAGTACTGCATACAG
GATTCCCTGCTGGTGGGCCAGCTGTTTTTTAAGTTTTTGCCCCATCTGGAGCTCTCGGCC
GTCGCGCGCTTGGCGGGTATTAACATCACCCGCACCATCTACGACGGCCAGCAGATCCGC
GTCTTTACGTGCCTGCTGCGCCTGGCCGACCAGAAGGGCTTTATTCTGCCGGACACCCAG
GGGCGATTTAGGGGCGCCGGGGGGGAGGCGCCCAAGCGTCCGGCCGCAGCCCGGGAGGAC
GAGGAGCGGCCAGAGGAGGAGGGGGAGGACGAGGACGAACGCGAGGAGGGCGGGGGCGAG
CGGGAGCCGGAGGGCGCGCGGGAGACCGCCGGCAGGCACGTGGGGTACCAGGGGGCCAGG
GTCCTTGACCCCACTTCCGGGTTTCACGTGAACCCCGTGGTGGTGTTCGACTTTGCCAGC
CTGTACCCCAGCATCATCCAGGCCCACAACCTGTGCTTCAGCACGCTCTCCCTGAGGGCC
GACGCAGTGGCGCACCTGGAGGCGGGCAAGGACTACCTGGAGATCGAGGTGGGGGGGCGA
CGGCTGTTCTTCGTCAAGGCTCACGTGCGAGAGAGCCTCCTCAGCATCCTCCTGCGGGAC
TGGCTCGCCATGCGAAAGCAGATCCGCTCGCGGATTCCCCAGAGCAGCCCCGAGGAGGCC
GTGCTCCTGGACAAGCAGCAGGCCGCCATCAAGGTCGTGTGTAACTCGGTGTACGGGTTC
ACGGGAGTGCAGCACGGACTCCTGCCGTGCCTGCACGTTGCCGCGACGGTGACGACCATC
GGCCGCGAGATGCTGCTCGCGACCCGCGAGTACGTCCACGCGCGCTGGGCGGCCTTCGAA
CAGCTCCTGGCCGATTTCCCGGAGGCGGCCGACATGCGCGCCCCCGGGCCCTATTCCATG
CGCATCATCTACGGGGACACGGACTCCATCTTTGTGCTGTGCCGCGGCCTCACGGCCGCC
GGGCTGACGGCCGTGGGCGACAAGATGGCGAGCCACATCTCGCGCGCGCTGTTTCTGCCC
CCCATCAAACTCGAGTGCGAAAAGACGTTCACCAAGCTGCTGCTGATCGCCAAGAAAAAG
TACATCGGCGTCATCTACGGGGGTAAGATGCTCATCAAGGGCGTGGATCTGGTGCGCAAA
AACAACTGCGCGTTTATCAACCGCACCTCCAGGGCCCTGGTCGACCTGCTGTTTTACGAC
GATACCGTCTCCGGAGCGGCCGCCGCGTTAGCCGAGCGCCCCGCGGAGGAGTGGCTGGCG
CGACCCCTGCCCGAGGGACTGCAGGCGTTCGGGGCCGTCCTCGTAGACGCCCATCGGCGC
ATCACCGACCCGGAGAGGGACATCCAGGACTTTGTCCTCACCGCCGAACTGAGCAGACAC
CCGCGCGCGTACACCAACAAGCGCCTGGCCCACCTGACGGTGTATTACAAGCTCATGGCC
CGCCGCGCGCAGGTCCCGTCCATCAAGGACCGGATCCCGTACGTGATCGTGGCCCAGACC
CGCGAGGTAGAGGAGACGGTCGCGCGGCTGGCCGCCCTCCGCGAGCTAGACGCCGCCGCC
CCAGGGGACGAGCCCGCCCCCCCCGCGGCCCTGCCCTCCCCGGCCAAGCGCCCCCGGGAG
ACGCCGTCGCCTGCCGACCCCCCGGGAGGCGCGTCCAAGCCCCGCAAGCTGCTGGTGTCC
GAGCTGGCCGAGGATCCCGCATACGCCATTGCCCACGGCGTCGCCCTGAACACGGACTAT
TACTTCTCCCACCTGTTGGGGGCGGCGTGCGTGACATTCAAGGCCCTGTTTGGGAATAAC
GCCAAGATCACCGAGAGTCTGTTAAAAAGGTTTATTCCCGAAGTGTGGCACCCCCCGGAC
GACGTGGCCGCGCGGCTCCGGACCGCAGGGTTCGGGGCGGTGGGTGCCGGCGCTACGGCG
GAGGAAACTCGTCGAATGTTGCATAGAGCCTTTGATACTCTAGCATGA

# Drug_Target_1_General_Function:
Replication, recombination and repair

# Drug_Target_1_General_References:
2839594	McGeoch DJ, Dalrymple MA, Davison AJ, Dolan A, Frame MC, McNab D, Perry LJ, Scott JE, Taylor P: The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol. 1988 Jul;69 ( Pt 7):1531-74.
2999714	Quinn JP, McGeoch DJ: DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein. Nucleic Acids Res. 1985 Nov 25;13(22):8143-63.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
338

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
136422

# Drug_Target_1_Name:
DNA polymerase

# Drug_Target_1_Number_of_Residues:
1235

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00136	DNA_pol_B
PF03104	DNA_pol_B_exo

# Drug_Target_1_Protein_Sequence:
>DNA polymerase
MFSGGGGPLSPGGKSAARAASGFFAPAGPRGASRGPPPCLRQNFYNPYLAPVGTQQKPTG
PTQRHTYYSECDEFRFIAPRVLDEDAPPEKRAGVHDGHLKRAPKVYCGGDERDVLRVGSG
GFWPRRSRLWGGVDHAPAGFNPTVTVFHVYDILENVEHAYGMRAAQFHARFMDAITPTGT
VITLLGLTPEGHRVAVHVYGTRQYFYMNKEEVDRHLQCRAPRDLCERMAAALRESPGASF
RGISADHFEAEVVERTDVYYYETRPALFYRVYVRSGRVLSYLCDNFCPAIKKYEGGVDAT
TRFILDNPGFVTFGWYRLKPGRNNTLAQPAAPMAFGTSSDVEFNCTADNLAIEGGMSDLP
AYKLMCFDIECKAGGEDELAFPVAGHPEDLVIQISCLLYDLSTTALEHVLLFSLGSCDLP
ESHLNELAARGLPTPVVLEFDSEFEMLLAFMTLVKQYGPEFVTGYNIINFDWPFLLAKLT
DIYKVPLDGYGRMNGRGVFRVWDIGQSHFQKRSKIKVNGMVNIDMYGIITDKIKLSSYKL
NAVAEAVLKDKKKDLSYRDIPAYYAAGPAQRGVIGEYCIQDSLLVGQLFFKFLPHLELSA
VARLAGINITRTIYDGQQIRVFTCLLRLADQKGFILPDTQGRFRGAGGEAPKRPAAARED
EERPEEEGEDEDEREEGGGEREPEGARETAGRHVGYQGARVLDPTSGFHVNPVVVFDFAS
LYPSIIQAHNLCFSTLSLRADAVAHLEAGKDYLEIEVGGRRLFFVKAHVRESLLSILLRD
WLAMRKQIRSRIPQSSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTI
GREMLLATREYVHARWAAFEQLLADFPEAADMRAPGPYSMRIIYGDTDSIFVLCRGLTAA
GLTAVGDKMASHISRALFLPPIKLECEKTFTKLLLIAKKKYIGVIYGGKMLIKGVDLVRK
NNCAFINRTSRALVDLLFYDDTVSGAAAALAERPAEEWLARPLPEGLQAFGAVLVDAHRR
ITDPERDIQDFVLTAELSRHPRAYTNKRLAHLTVYYKLMARRAQVPSIKDRIPYVIVAQT
REVEETVARLAALRELDAAAPGDEPAPPAALPSPAKRPRETPSPADPPGGASKPRKLLVS
ELAEDPAYAIAHGVALNTDYYFSHLLGAACVTFKALFGNNAKITESLLKRFIPEVWHPPD
DVAARLRTAGFGAVGAGATAEETRRMLHRAFDTLA

# Drug_Target_1_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P04293

# Drug_Target_1_SwissProt_Name:
DPOL_HHV11

# Drug_Target_1_Synonyms:
EC 2.7.7.7

# Drug_Target_1_Theoretical_pI:
7.31

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Nucleus

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X04370

# Drug_Target_2_GenBank_ID_Protein:
60016

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ORF28

# Drug_Target_2_Gene_Sequence:
>3585 bp
TTAACTTTGATGGAGAATTGCTTTTGGAATACAAAAGACTCTACGCATTATTTGATGACT
TTGTTCCTCCTCGGTGATTTCAGCTTCAGTGTTCATTTTATTATCCCAGCACGGGGCGTG
TATACAAACAAAGCCTGCCGCCTGCAAGCGGTTTAGCATTTTAACGTTAACAACTCGTGT
CTCTGGAATAAAACGTTTTAAAAGCCGTTCTGTGAGTTTAGTGTCGTTTCCAAATAACGC
CTTAAAAGTTACACTCGCCGTCCCAATGAGATGAGAAAAATAATAGTCAATGTTTAAAGA
CAGCCCGTGTGATGTTACGTGAATGGGATCTTCCGCTAAGTCAGATATTATTAACTTACG
CTTTGCTTCCCCACACCGTTTACCTGCGGTATTCTGTAAAGGATCTCCACGTAGCAAAGC
TACACTTTTTGCATCAGCCTCCACTTCGTCTGTGGGGGCCACAATAACATAAGGGATGCG
TTCTCGAACGTTTGGGATTTGACCCTGTCTCATTACTAATTTATAATATACTGTTAAGTG
AGCCAAGCGACGGTTTATGTAGGCGGATGGTGGACGACTAAGCTCGGCCGTCATAACAAA
CTTATTAATATCCAATTTGGGTGATGTAATCTGGCGATGTGCATCTGCAATTATGCGTCC
AAACCCGGCCATCCCAGACGGCATGGCCCGTCTATTCCATTCAGCAATGGAAACACACGA
CGCCTCCGCCGCAGCACGCGAGACGGTGTCGTCATATAACAACAGTTCTACAAGTTTGCG
GGCATAATCGTTAATAAATTGACAGTTGTTTTTTCTAACCAAGTCGACTCCCTTCATTAA
AACCTTTCCGCCGTAAATTACCCCAATGTACTTTTTCTTTGTTATAAGCAAAAGTTTTAT
AAAAGTTTTTTCACACTCCAACTTTATAGGAGGACAAAACAGAGCCGTTGAAATTATATG
TGCCATTTTCTCGCCGATTTTAGCTATCCCCTCAACACTAACACCCTTGAATCGGATAAA
CACAGAATCCGTATCTCCATATATAACCTTTACCTCGTACGCTTTTTGGGAGAGAACGCT
ACTTTCAATGTCTGGAAACGCTGTAATAAAACGTTCAAATGCGGCCCAGTTATTATGAAT
ATAATCTCTGGTACTTAATAACATTTGACGGCCAATTGTAGTGACAGTGGCCGCTACGTA
TAAACATGGCAGAAATCCCTGCGCAACTCCAGTAAAACCGTACACGGAATTACAAACTAC
TTTTATCGCGGCTTGTTGTTTGTCTAATAACACTGCTTCATCTGAAGAACTTCCGGGTAT
GCGCGCTCTAATAGCCTTGCGCATAGCCAACCAGTCTTTTAAAAGAACACCCAGCAGACT
TTCTCGAACGTTAGAGCGCACAAAAAAAAGACGTTTTCCTCCAACTGTAAAGGTGGCATA
ATCGGATGGATTCAAACGTTTAACCGTCTCAAAATTTAACGTTAGCGTGGTAAAACATAA
GTTATGGGCCTGAATTATACTTGGATATAAACTTGCAAAATCCAATACGACCACCGGATC
GATATAAAATCCCGTATCAGGGTCAAAAACCCTGGCTCCTTTATATCCTACATTTCGCCC
ACTTGACGTACCAGTGGGAGAAACGCTCTCGTCTTCATCCATCTCTTCCTCAACATCCCC
GACATCGGGAATAACATCCTTATATTCAAAAGTAGCTGGGTATCCCCCATCGGGTAAAAT
AAATCCTCGAGACGAAGCCAGTCCTAATAAACAGGTGTAAATCCTAACCTGCTGTCCGTC
GTAAATAGCCTTGGTTAAAGTAATTCTAGCTAGCCTTGCAACCGCGGATAACTCAAGGTG
TGGTAAATATTTAAAAAACAGTTTCCCCACAAGAGCCGAGTCTTGTATACAATATTCACC
AATAATTCCTCGTGTATTCGGTCCACTAGCGTAATATCCCGGAATGTCTTTGTAGGGCAA
ATCTCTCTTGGACTCATTTAGAGCTTCACGTGCAACCGAATCTAATTTATAACTCGAGAG
TTTTAATTTTTCAGTTGCAATTGCATACATATCCAGAGATATGAGACCGTTGATCTTTAC
CTTGCTTCGTCGCTGAAATCCGGATTTGCCAACATCCCATATCTTAAACAGACCCCCACG
GTTTATACTGCCATAACCATCAAGCTTGAGACTGTATATAGAATTAAGTTTCTCCATAAT
AAACGCCCAATCAAAATTAACAATGTTATAACCTGTGGCAAACTCGGGAGCGTACTGTTT
TACGAGGGTCATAAATGCAATTAATAGCTCGAATTCACTATCAAACTCCAGCACAGTCGG
CTCCGGTAACCCCGCGTCCTTCATTTCTTGTACATACCTTTGTGGTAAGTCACAAGAGCC
AAGGGAAAACAGTAAAATGTGTTCTAAAGACTGTCGAGGGATTGAATATAATAGACAAGA
AATTTGGATTACAAGATCCTCCAGATGTGTTGCATCGGGAAACGCCAGCTCATTAGATCC
TCCTGATTTACATTCAATATCGAAACATAACAACTTGTAGTCAGGCCATGAGTCATCGTT
TGGTATAGCCTGCAGATTATCCGACATGCAGTCAATTTCAACGTCGCTTAACGTTAATTG
GCGACTTGCCGGTCGAACTCGAACACGTTCCCCATCAACTCCAGGTTTTAGTTGATACCA
ACCAAAACTAACAAAGCCGGGATTATCCATTAGAAAACGAGTGGTAGCGTCTACCCGACC
TTCATACTTTTTCAACTCCGGGTGAAAGTTATCACAAAGATAATTTGTAAATTTAGATGA
GGGAGAATACACCCTGTAAAACGCACATGGCTGTGTATCGTAGTAATAAACATCTGTGCG
CTCAATAACCTCAACGCGAAAGCTTTCTGGAGATGCGCTTTTAAACGAGGTACCATGAAA
AGCGTTCTTGTCTCCATTTAACGTTGCATCATTTTGTGTTATCATAGAACTGCGTAAACA
CTCGGCAAGTAATACAGATAACTCGCTACCGGAACGTATGCCACAAGCGGTATCCACCTC
GGCTTTGTTTATATAAAAATATTGACAGATGCCGTATACATGAACTGCCACCCTTTTTCC
ACATCGGGACATGCCAAGTAAAGTAATAACGGTACCAAGCGGTCGTGTTGCAGTTGCAAA
CCGGGATACATCTCCATTAGACGCGGCTTCTGTTGTTTCGACAATATCATATACATGGAA
TGTGTTAAAGCGGGGGTCAAACTTATCCCCACGAAAGTCGATTTCCCCCCAAATATTCAC
GCGTCTAGGCCAGGGGCTGGAACAACGAAAATCCAGAATCGGAACTTCTTTTCCATTACA
GTAAACTTTAGGCGGTCGACTAAGTGTACCGACGTGAACCCCCTTTCGTTCTTCCATGGG
CACATCTTCATCTAAACATTTAGGGGCCAAAAATTGAAACGATGACATGGTAGTTTTGTA
ACTATGAAGAAATTCTCTGTTACTACCGCGCCCGGTTCTTGGGTTATATTTAATCCCTGA
TGCTTGGGTTAAAAAGGGATTACAAAACCCCGTTCTGATCGCCAT

# Drug_Target_2_General_Function:
Replication, recombination and repair

# Drug_Target_2_General_References:
3018124	Davison AJ, Scott JE: The complete DNA sequence of varicella-zoster virus. J Gen Virol. 1986 Sep;67 ( Pt 9):1759-816.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
697

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
134049

# Drug_Target_2_Name:
DNA polymerase

# Drug_Target_2_Number_of_Residues:
1194

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00136	DNA_pol_B
PF03104	DNA_pol_B_exo

# Drug_Target_2_Protein_Sequence:
>DNA polymerase
MAIRTGFCNPFLTQASGIKYNPRTGRGSNREFLHSYKTTMSSFQFLAPKCLDEDVPMEER
KGVHVGTLSRPPKVYCNGKEVPILDFRCSSPWPRRVNIWGEIDFRGDKFDPRFNTFHVYD
IVETTEAASNGDVSRFATATRPLGTVITLLGMSRCGKRVAVHVYGICQYFYINKAEVDTA
CGIRSGSELSVLLAECLRSSMITQNDATLNGDKNAFHGTSFKSASPESFRVEVIERTDVY
YYDTQPCAFYRVYSPSSKFTNYLCDNFHPELKKYEGRVDATTRFLMDNPGFVSFGWYQLK
PGVDGERVRVRPASRQLTLSDVEIDCMSDNLQAIPNDDSWPDYKLLCFDIECKSGGSNEL
AFPDATHLEDLVIQISCLLYSIPRQSLEHILLFSLGSCDLPQRYVQEMKDAGLPEPTVLE
FDSEFELLIAFMTLVKQYAPEFATGYNIVNFDWAFIMEKLNSIYSLKLDGYGSINRGGLF
KIWDVGKSGFQRRSKVKINGLISLDMYAIATEKLKLSSYKLDSVAREALNESKRDLPYKD
IPGYYASGPNTRGIIGEYCIQDSALVGKLFFKYLPHLELSAVARLARITLTKAIYDGQQV
RIYTCLLGLASSRGFILPDGGYPATFEYKDVIPDVGDVEEEMDEDESVSPTGTSSGRNVG
YKGARVFDPDTGFYIDPVVVLDFASLYPSIIQAHNLCFTTLTLNFETVKRLNPSDYATFT
VGGKRLFFVRSNVRESLLGVLLKDWLAMRKAIRARIPGSSSDEAVLLDKQQAAIKVVCNS
VYGFTGVAQGFLPCLYVAATVTTIGRQMLLSTRDYIHNNWAAFERFITAFPDIESSVLSQ
KAYEVKVIYGDTDSVFIRFKGVSVEGIAKIGEKMAHIISTALFCPPIKLECEKTFIKLLL
ITKKKYIGVIYGGKVLMKGVDLVRKNNCQFINDYARKLVELLLYDDTVSRAAAEASCVSI
AEWNRRAMPSGMAGFGRIIADAHRQITSPKLDINKFVMTAELSRPPSAYINRRLAHLTVY
YKLVMRQGQIPNVRERIPYVIVAPTDEVEADAKSVALLRGDPLQNTAGKRCGEAKRKLII
SDLAEDPIHVTSHGLSLNIDYYFSHLIGTASVTFKALFGNDTKLTERLLKRFIPETRVVN
VKMLNRLQAAGFVCIHAPCWDNKMNTEAEITEEEQSHQIMRRVFCIPKAILHQS

# Drug_Target_2_Reaction:
deoxynucleoside triphosphate + DNAn = diphosphate + DNAn+1

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P09252

# Drug_Target_2_SwissProt_Name:
DPOL_VZVD

# Drug_Target_2_Synonyms:
EC 2.7.7.7

# Drug_Target_2_Theoretical_pI:
7.94

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB00426
